Alisa Koch

I’m a board-certified pharmaceutical Medical Affairs and Clinical Development leader with deep expertise across autoimmune (AI) strategy, clinical research and development, medical affairs, and medical education. I’m known for global-level team support, strong customer experience, and a lifelong commitment to medical/scientific work that improves patient outcomes.

In my latest role, I led Medical Engagement in Clinical Development and Medical Affairs for an oncology CAR-T company focused on AI diseases. I introduced the company to top autoimmune KOLs at EULAR and ACR, contributed to phase I/II trial design for SLE and SLE nephritis (including FDA-related protocol revisions), mapped AI strategy, and supported scientific data dissemination through congress abstracts.

Previously at Eli Lilly and Company, I held senior Medical Fellow/Vice President Immunology leadership roles across Medical Affairs and Clinical Development for RA/Covid-19 and helped develop and launch an AI platform. I successfully launched Olumiant and Taltz, set brand strategy and business plans, designed clinical trials, served as final reviewer for medical escalations and FAQs, and authored ~250 peer-reviewed publications, including work in major journals.

I also bring strong investigator-initiated research (IIR/IIT) and regulatory expertise—acting as a medical reviewer for the Olumiant NDA to the FDA, leading IIT program evaluations, and driving medical data dissemination (SDD) across Medical and Marketing needs. Across my background in academia and pharma, I’ve built training roadmaps, organized advisory boards, and partnered with business leaders to advance translational research and launch readiness.